高级搜索
曾治民, 欧阳玉茗, 何静, 熊士忠, 钟琼. 胸部序贯放疗较巩固放疗延长广泛期小细胞肺癌无进展生存期[J]. 肿瘤防治研究, 2017, 44(3): 209-213. DOI: 10.3971/j.issn.1000-8578.2017.03.011
引用本文: 曾治民, 欧阳玉茗, 何静, 熊士忠, 钟琼. 胸部序贯放疗较巩固放疗延长广泛期小细胞肺癌无进展生存期[J]. 肿瘤防治研究, 2017, 44(3): 209-213. DOI: 10.3971/j.issn.1000-8578.2017.03.011
ZENG Zhimin, OUYANG Yuming, HE Jing, XIONG Shizhong, ZHONG Qiong. Sequential Thoracic Radiotherapy Improves Progression Free Survival of Patients with Extensive-disease Small Cell Lung Cancer, Compared with Consolidative Thoracic Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 209-213. DOI: 10.3971/j.issn.1000-8578.2017.03.011
Citation: ZENG Zhimin, OUYANG Yuming, HE Jing, XIONG Shizhong, ZHONG Qiong. Sequential Thoracic Radiotherapy Improves Progression Free Survival of Patients with Extensive-disease Small Cell Lung Cancer, Compared with Consolidative Thoracic Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 209-213. DOI: 10.3971/j.issn.1000-8578.2017.03.011

胸部序贯放疗较巩固放疗延长广泛期小细胞肺癌无进展生存期

Sequential Thoracic Radiotherapy Improves Progression Free Survival of Patients with Extensive-disease Small Cell Lung Cancer, Compared with Consolidative Thoracic Radiotherapy

  • 摘要:
    目的 比较胸部序贯放疗与巩固放疗在广泛期小细胞肺癌(ED-SCLC)的意义。
    方法 收集2010年1月至2013年6月期间接受胸部放疗的ED-SCLC患者102例。运用Kaplan-Meier法对序贯胸部放疗和巩固放疗的2组患者的无进展生存(PFS)及总生存(OS)进行生存分析。
    结果 序贯放疗组中位PFS、1年PFS率依次为11.0月、39.6%,巩固放疗组依次为9.4月、7.7%(P=0.000)。序贯放疗组中位、1年、2年OS率依次为15.0月、77.7%、4.6%;巩固放疗组依次为14.2月、82.4%、2.4%(P=0.58)。单因素分析发现PS评分=0分,化疗 > 3程及序贯放疗改善PFS。多因素分析发现化疗 > 3程及序贯放疗是影响PFS的两个独立预后因子。亚组分析发现无论化疗≤3程还是 > 3程,序贯放疗组PFS皆延长。
    结论 胸部序贯放疗可延长部分高选择性ED-SCLC患者的PFS。化疗疗程 > 3程和序贯放疗是其两个独立预后因素。

     

    Abstract:
    Objective To explore the effect of sequential thoracic radiotherapy on extensive-disease small cell lung cancer (ED-SCLC) compared with consolidative radiotherapy.
    Methods We collected 102 patients with ED-SCLC who received thoracic radiotherapy from January 2010 to June 2013. The progression free survival (PFS) and overall survival (OS) of two radiotherapy arms (sequential vs. consolidative radiotherapy) were analyzed by Kaplan-Meier curve method.
    Results The median PFS and 1-year PFS rates were 11.0 month, and 39.6% in sequential thoracic radiotherapy group, 9.4 month and 4.6% in consolidative radiotherapy group (P=0.000). The median OS, 1-year and 2-year OS rates were 15.0m, 77.7% and 4.6% in sequential group, 14.2m, 82.4% and 2.4% in consolidative group (P=0.58). Univariate analysis showed that performance status (PS) score (=0), cycles of chemotherapy ( > 3) and sequential thoracic radiotherapy were significantly associated with better PFS (P=0.005) and multivariate analysis indicated that cycles of chemotherapy ( > 3) and sequential radiotherapy were independent favorable prognostic factors. Further, subgroup analysis showed that whether chemotherapy cycles > 3 or≤3, the PFS of patients who received sequential thoracic radiotherapy was longer.
    Conclusion Sequential thoracic radiotherapy could improved the PFS of some highly selective patients with ED-SCLC. Cycles of chemotherapy ( > 3) and sequential thoracic radiotherapy are two independent prognostic factors.

     

/

返回文章
返回